| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0025-7125(05)70509-5 |
| P698 | PubMed publication ID | 9012759 |
| P50 | author | Michelle A. Petri | Q67485110 |
| P2860 | cites work | Lupus anticoagulant and heparin-associated bleeding | Q71933468 |
| Normal fetal growth in women with antiphospholipid syndrome treated with high-dose intravenous immunoglobulin (IVIG) | Q72022440 | ||
| Down-regulation of maternal antiphospholipid antibodies during early pregnancy and pregnancy outcome | Q72059538 | ||
| Acquired free protein S deficiency is associated with antiphospholipid antibodies and increased thrombin generation in patients with systemic lupus erythematosus | Q72140744 | ||
| Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus | Q72214273 | ||
| A prospective study on pregnancy risk of antiphospholipid antibodies in association with systemic lupus erythematosus | Q72284377 | ||
| Low-dose aspirin for prevention of pregnancy losses in women with primary antiphospholipid syndrome | Q72347443 | ||
| Inhibition of prostacyclin release by endothelial binding anticardiolipin antibodies in thrombosis-prone patients with systemic lupus erythematosus and the antiphospholipid syndrome | Q72373656 | ||
| Arterial thrombosis, intrauterine death and "lupus" antiocoagulant: detection of immunoglobulin interfering with prostacyclin formation | Q72451284 | ||
| Intravenous immunoglobulin therapy for the antiphospholipid syndrome in pregnancy | Q72547160 | ||
| The management of thrombosis in the antiphospholipid-antibody syndrome | Q72619159 | ||
| Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients | Q72671950 | ||
| Unexplained thrombosis and factor V Leiden mutation | Q72688139 | ||
| Transesophageal echocardiographic detection of multiple mitral valve masses in primary antiphospholipid syndrome with stroke | Q72746735 | ||
| Combined corticosteroid and aspirin treatment for the high risk lupus pregnancy | Q72838416 | ||
| Anti-idiotypes against antiphospholipid antibodies are present in normal polyspecific immunoglobulins for therapeutic use | Q72857704 | ||
| Hypercoagulable states | Q72939029 | ||
| Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H) | Q24558202 | ||
| Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus | Q28261335 | ||
| Prothrombinase activity of human platelets is inhibited by beta 2-glycoprotein-I | Q28304443 | ||
| Beta 2-glycoprotein-I (apo-H) inhibits the release reaction of human platelets during ADP-induced aggregation | Q28305356 | ||
| Double heart valve replacement disclosing antiphospholipid syndrome | Q33354607 | ||
| Induction of experimental anti-phospholipid syndrome associated with SLE following immunization with human monoclonal pathogenic anti-DNA idiotype | Q33355283 | ||
| Anticardiolipin antibodies in heparin-associated thrombocytopenia | Q33356781 | ||
| Induction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anticardiolipin antibody (H-3) | Q33364820 | ||
| Antiphospholipid Thrombosis: Clinical Course after the First Thrombotic Event in 70 Patients | Q33369688 | ||
| In vivo efficacy of intravenous gammaglobulins in patients with lupus anticoagulant is not mediated by an anti-idiotypic mechanism | Q33373724 | ||
| Cerebral ischemic events associated with endocarditis, retinal vascular disease, and lupus anticoagulant | Q33381987 | ||
| Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies | Q33388194 | ||
| Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance | Q33392960 | ||
| Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients | Q33438663 | ||
| Myocardial infarction in a young man with systemic lupus erythematosus, deep vein thrombosis, and antibodies to phospholipid | Q33446337 | ||
| Coagulation screen is more specific than the anticardiolipin antibody ELISA in defining a thrombotic subset of lupus patients | Q33447381 | ||
| Thrombosis, recurrent fetal loss, and thrombocytopenia. Predictive value of the anticardiolipin antibody test | Q33453407 | ||
| Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus | Q33458388 | ||
| Thrombocytopenia in SLE and related autoimmune disorders: association with anticardiolipin antibody | Q33459225 | ||
| Thrombosis in patients with the lupus anticoagulant | Q33486691 | ||
| A family study of anticardiolipin antibodies and associated clinical conditions | Q33487561 | ||
| Lupus anticoagulant, heparin use, and thrombocytopenia in patients with chronic thromboembolic pulmonary hypertension: a preliminary report | Q33488491 | ||
| Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin | Q33489438 | ||
| Role of IL-3 in the antiphospholipid syndrome | Q33490039 | ||
| Pregnancy outcome in women with antiphospholipid antibodies | Q33493247 | ||
| The effect of aspirin on recurrent fetal loss in experimental antiphospholipid syndrome | Q33493954 | ||
| The effect of intravenous gamma-globulin on the induction of experimental antiphospholipid syndrome | Q33494140 | ||
| Prevention of fetal loss in experimental antiphospholipid syndrome by in vivo administration of recombinant interleukin-3 | Q33494657 | ||
| Avascular necrosis of bone in systemic lupus erythematosus: possible role of haemostatic abnormalities | Q33561944 | ||
| Prospective study of fluctuations of lupus anticoagulant activity and anticardiolipin antibody titre in patients with systemic lupus erythematosus | Q33564380 | ||
| Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment | Q33565796 | ||
| Antiphospholipid antibodies (aPL) in systemic lupus erythematosus. Are they specific tools for the diagnosis of aPL syndrome? | Q33566129 | ||
| Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates | Q33905952 | ||
| Mutation in blood coagulation factor V associated with resistance to activated protein C. | Q34340007 | ||
| Use of antithrombotic agents during pregnancy | Q35373440 | ||
| Lupus anticoagulant activity of autoimmune antiphospholipid antibodies is dependent upon beta 2-glycoprotein I | Q35822631 | ||
| (NZW x BXSB)F1 hybrid. A model of acute lupus and coronary vascular disease with myocardial infarction | Q36345299 | ||
| Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes | Q36363024 | ||
| Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis | Q36747001 | ||
| Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation events and antigenic spread in systemic lupus erythematosus | Q37722431 | ||
| Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components | Q38508071 | ||
| The frequency of lupus anticoagulant in systemic lupus erythematosus. A study of sixty consecutive patients by activated partial thromboplastin time, Russell viper venom time, and anticardiolipin antibody level | Q39289964 | ||
| Hydroxychloroquine and postoperative thromboembolism after total hip replacement | Q39531655 | ||
| Cerebrovascular ischemia associated with lupus anticoagulant | Q39593049 | ||
| Lupus anticoagulant and pregnancy | Q39849377 | ||
| Cognitive deficit associated with rheumatic diseases: neuropsychological perspectives | Q40422622 | ||
| Antiphospholipid antibodies and eicosanoids | Q40558516 | ||
| Thoughts on the mechanism of pregnancy loss associated with the antiphospholipid syndrome | Q40558522 | ||
| Assays for detection of antiphospholipid antibodies | Q40558527 | ||
| Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematosus, lupus-like disease, and the primary antiphospholipid syndrome | Q41238775 | ||
| Obstetric performance in patients with the lupus anticoagulant and/or anticardiolipin antibodies | Q41837702 | ||
| Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group | Q42287205 | ||
| Detection of endothelial cell-reactive immunoglobulin in patients with anti-phospholipid antibodies | Q43719415 | ||
| Effectiveness of prednisolone/aspirin therapy for recurrent aborters with antiphospholipid antibody | Q43960513 | ||
| Successful treatment in two women with antiphospholipid antibodies and refractory pregnancy losses with intravenous immunoglobulin infusions | Q44067471 | ||
| Anticardiolipin antibodies and lupus anticoagulants comprise separate antibody subgroups with different phospholipid binding characteristics. | Q45239170 | ||
| Deep Vein Thrombosis: Prevalence of Etiologic Factors and Results of Management in 100 Consecutive Patients | Q46010793 | ||
| Valvular heart disease in the primary antiphospholipid syndrome | Q46730841 | ||
| Prevention of fetal loss in experimental antiphospholipid syndrome by low-molecular-weight heparin | Q47389805 | ||
| Cardioembolic caudate infarction as a cause of hemichorea in lupus anticoagulant syndrome | Q48295399 | ||
| Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis | Q48394757 | ||
| Congenic autoimmune murine models of central nervous system disease in connective tissue disorders | Q48766365 | ||
| Corticosteroids and neuropsychological functioning in patients with systemic lupus erythematosus. | Q51131677 | ||
| Resistance to activated protein C as a basis for venous thrombosis. | Q54214042 | ||
| Lupus anticoagulant and the fibrinolytic system in young patients with stroke | Q58421453 | ||
| Antiphospholipid Antibodies and Endothelial Cells | Q62395221 | ||
| Serum apolipoprotein H levels in systemic lupus erythematosus are not influenced by antiphospholipid antibodies | Q67482133 | ||
| The thrombotic diathesis associated with the presence of phospholipid antibodies may be due to low levels of free protein S | Q67545591 | ||
| Prevention of anticardiolipin antibody-related pregnancy losses with prednisone and aspirin | Q67566965 | ||
| A prospective, controlled multicenter study on the obstetric risks of pregnant women with antiphospholipid antibodies | Q67586423 | ||
| Antiendothelial Cell Antibodies in Patients with the Antiphospholipid Syndrome | Q67886354 | ||
| Association of anti-beta 2 glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus | Q68008000 | ||
| Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease | Q68091809 | ||
| Antiphospholipid antibodies and atherosclerosis | Q68116700 | ||
| Myocardial infarction caused by cardiac microvasculopathy in a patient with the primary antiphospholipid syndrome | Q68125663 | ||
| Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment | Q68139494 | ||
| Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus | Q68153286 | ||
| A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians | Q68227750 | ||
| In vitro activation of the contact activation system (Hageman factor system) in plasma by acidic phospholipids and the inhibitory effect of I on this activation | Q68310414 | ||
| Increased thromboxane formation in patients with antiphospholipid syndrome | Q68379902 | ||
| Spontaneous recurrent fetal wastage and autoimmune abnormalities: a study of fourteen cases | Q68796709 | ||
| Skin lesions associated with circulating lupus anticoagulant | Q69193395 | ||
| Neurological disease associated with antiphospholipid antibodies | Q69624901 | ||
| Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy | Q69742234 | ||
| Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular events | Q69874910 | ||
| Prednisone does not prevent recurrent fetal death in women with antiphospholipid antibody | Q69946465 | ||
| Hyperhomocysteinemia: an independent risk factor for vascular disease | Q70131136 | ||
| Chorea in systemic lupus erythematosus and "lupus-like" disease: association with antiphospholipid antibodies | Q70346602 | ||
| An unusual syndrome of a devastating noninflammatory vasculopathy associated with anticardiolipin antibodies: report of two cases | Q70365615 | ||
| The relationship between lupus anticoagulants and antibodies to phospholipid | Q70370974 | ||
| Prevention of Postoperative Deep Venous Thrombosis and Pulmonary Embolism | Q70549361 | ||
| Umbilical artery and ductal blood flow velocities in patients treated with aspirin and prednisone for presence of anticardiolipin antibody | Q70712836 | ||
| In vitro lupus anticoagulant neutralizing activity of intravenous immunoglobulin | Q70762184 | ||
| Systemic lupus erythematosus and habitual abortion. Case report | Q71351766 | ||
| Decidual vasculopathy and extensive placental infarction in a patient with repeated thromboembolic accidents, recurrent fetal loss, and a lupus anticoagulant | Q71593361 | ||
| Interaction of heparin with antiphospholipid antibodies (APA) from the sera of women with recurrent pregnancy loss (RPL) | Q71908100 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 151-177 | |
| P577 | publication date | 1997-01-01 | |
| P1433 | published in | Medical Clinics of North America | Q15761972 |
| P1476 | title | Pathogenesis and treatment of the antiphospholipid antibody syndrome | |
| P478 | volume | 81 |
| Q35574348 | A Cutaneous Manifestation of Antiphospholipid Antibody Syndrome |
| Q44057192 | Abnormal regional cerebral blood flow in primary antiphospholipid antibody syndrome patients with normal magnetic resonance imaging findings. A preliminary report |
| Q33336296 | Anti-cardiolipin and anti-beta2 glycoprotein I antibodies in Indian patients with systemic lupus erythematosus: association with the presence of seizures |
| Q36256231 | Anticardiolipin antibodies and ocular disease |
| Q79245648 | Anticardiolipin antibodies in various diseases in Taiwan: a retrospective analysis |
| Q74616049 | Antiphospholipid antibodies are a risk factor for early renal allograft failure: isolation of antiphospholipid antibodies from a thrombosed renal allograft |
| Q35104711 | Antiphospholipid antibodies: discovery, definitions, detection and disease |
| Q41713369 | Antiphospholipid antibody syndrome: current concepts |
| Q35984353 | Aortoiliac thrombosis in antiphospholipid syndrome-case report and literature review |
| Q52008946 | Behavioral and cognitive deficits occur only after prolonged exposure of mice to antiphospholipid antibodies. |
| Q33332894 | Cerebral blood flow and glucose metabolism in multi-infarct-dementia related to primary antiphospholipid antibody syndrome |
| Q77769404 | Evidence that anticardiolipin antibodies are independent risk factors for atherosclerotic vascular disease |
| Q34380569 | Fluctuation in the Levels of Immunoglobulin M and Immunoglobulin G Antibodies for Cardiolipin and β2-Glycoprotein among Healthy Pregnant Women |
| Q35549772 | How to treat women with antiphospholipid antibodies in pregnancy? |
| Q33338363 | Hyperactivity in a mouse model of the antiphospholipid syndrome |
| Q58647328 | IgA Anticardiolipin in Patients with Gastroenteric Tumor |
| Q28191467 | Increased circulating platelet-leucocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis |
| Q40874242 | Interleukin-3: Promises and Perspectives |
| Q61943926 | LUPUS ANTICOAGULANTS AND ANTIPHOSPHOLIPID ANTIBODIES |
| Q34250901 | Neuropsychiatric lupus |
| Q43568071 | Ocular features associated with anticardiolipin antibodies: a descriptive study |
| Q35008513 | Phospholipid autoantibodies: time for a new immuno-assay? |
| Q47719673 | Platelet activation and turnover in the primary antiphospholipid syndrome |
| Q34674429 | Primary anti-phospholipid antibody syndrome (APS): current concepts |
| Q37281860 | Primary antiphospholipid antibody syndrome: neuroradiologic findings in 11 patients |
| Q74592014 | Recurrent retinal artery occlusion after the disappearance of lupus anticoagulant |
| Q34982135 | Rheumatology. |
| Q77421193 | Scleritis as the presenting sign of primary antiphospholipid syndrome |
| Q79245668 | Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy |
| Q58004012 | Testing strategies for diagnosing lupus anticoagulant: Decision analysis |
| Q44396576 | Using 99mTc HMPAO brain SPECT to evaluate the effects of anticoagulant therapy on regional cerebral blood flow in primary antiphospholipid antibody syndrome patients with brain involvement-a preliminary report |
| Q33722879 | Women's health |
Search more.